Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

I CAN PhIII interim analysis met primary endpoint

April 21, 2026

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

April 20, 2026

Third tozorakimab positive Phase III in COPD

April 20, 2026

SLE Market Evolution Accelerates as AstraZeneca’s Saphnelo SC Emerges as a Likely Key Challenger to GSK’s Benlysta

April 13, 2026

Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

April 9, 2026

Matan Companies Breaks Ground on New Strip Retail Development in Gaithersburg, MD

April 6, 2026

Syneron Bio Announces Completion of $150 Million Series B Financing

April 3, 2026

IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

April 2, 2026

Imfinzi+Imjudo improves PFS in early liver cancer

April 2, 2026

Total Voting Rights and Admission of Shares

April 1, 2026

Efzimfotase alfa Ph3 program show positive results

March 31, 2026

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

March 27, 2026

Tozorakimab met OBERON/TITANIA primary endpoints

March 27, 2026

Amani Therapeutics Closes $25 Million Series A to Advance AM-01, a Potential Best-in-Class Therapy for Serious Neuropsychiatric Disorders

March 23, 2026

Notification of Admission of Shares

March 20, 2026

UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer

March 19, 2026

Saphnelo Surpasses Benlysta in CLE as Physicians Expand Use of Biologics Ahead of Key 2027 Catalysts

March 17, 2026

Imfinzi approved in EU for early gastric cancer

March 16, 2026

Saphnelo (AstraZeneca) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

March 10, 2026

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

March 9, 2026

Third Annual Bio-IT World Venture, Innovation & Partnering Conference Returns to Boston May 19

March 5, 2026

Total Voting Rights

March 2, 2026

AstraZeneca prices a $2bn bond offering

February 26, 2026

Filing of Form 20-F with SEC

February 25, 2026

Annual Financial Report

February 24, 2026

Directorate change

February 24, 2026

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

February 20, 2026

Fixed-duration Calquence combo approved in US

February 20, 2026

ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

February 19, 2026

Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development

February 18, 2026

Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035

February 18, 2026

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

February 13, 2026

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

February 11, 2026

AstraZeneca results: FY and Q4 2025

February 10, 2026

Final Results

February 10, 2026

Levicept Announces the Appointment of James Sandy as Chief Development Officer

February 4, 2026

DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

February 3, 2026

DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

February 3, 2026

Update on Saphnelo subcutaneous administration

February 3, 2026

AstraZeneca begins trading on the New York Stock Exchange

February 2, 2026

Imfinzi recommended in EU for early gastric cancer

February 2, 2026

AstraZeneca begins trading on NYSE

February 2, 2026

AstraZeneca agrees obesity and T2D deal with CSPC

January 30, 2026

AstraZeneca invests $15bn in China through 2030

January 29, 2026

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

January 28, 2026

Multiply Labs Announces New Collaboration to Automate Cell Therapy Manufacturing with Robotics

January 27, 2026

AstraZeneca's Tagrisso® and Calquence® Among First Oncology Treatments Granted Accelerated Access Through Ontario's FAST Program

January 23, 2026

AstraZeneca to complete direct listing on NYSE

January 20, 2026

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

January 19, 2026

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 242 decks. Every deck is listed under its year.